LYNN C HARTMANN, M.D.
Osteopathic Medicine at 1 St, Rochester, MN
License number
Minnesota 30449
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
200 1St St SW, Rochester, MN 55905
Phone
(507) 284-2511
Organization information
See more information about LYNN C HARTMANN at bizstanding.comMayo Clinic - LYNN C Hartmann MD
200 1 St SW #W4, Rochester, MN 55905
Categories:
Government Contractors, Physicians & Surgeons
Phone:
(507) 284-2511 (Phone)
Professional information
Lynn C Hartmann, Rochester MN
Specialties:
Oncologist
Address:
200 1St St Sw, Rochester, MN 55905
Education:
Northwestern University, Feinberg School of Medicine - Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)
Dr. Lynn C Hartmann, Rochester MN - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
Mayo Clinic
200 1St St SW, Rochester 55905
(507) 284-2511 (Phone)
200 1St St SW, Rochester 55905
(507) 284-2511 (Phone)
Certifications:
Internal Medicine, 1986, Medical Oncology, 1989
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Northwestern University The Feinberg School Of Medicine
Graduated: 1983
University Ia Hosps/Clins
Graduated: 1984
Graduated: 1986
Mayo Med Fdn
Northwestern University The Feinberg School Of Medicine
Graduated: 1983
University Ia Hosps/Clins
Graduated: 1984
Graduated: 1986
Mayo Med Fdn
Assessing Atypical Hyperplasia Patients For The Risk Of Developing Breast Cancer
US Patent:
2011013, Jun 9, 2011
Filed:
Dec 6, 2010
Appl. No.:
12/960894
Inventors:
Lynn C. Hartmann - Rochester MN, US
Marlene Frost - Burnsville MN, US
Carol Reynolds - Rochester MN, US
Vernon Pankratz - Rochester MN, US
Marlene Frost - Burnsville MN, US
Carol Reynolds - Rochester MN, US
Vernon Pankratz - Rochester MN, US
International Classification:
C12Q 1/68
US Classification:
435 614
Abstract:
This document provides methods and materials involved in assessing the risk of developing breast cancer in patients with atypical hyperplasia. For example, methods and materials for using the level of Ki67 expression (e.g., percent Ki67cells or Ki67 staining intensity) to determine if a patient with atypical hyperplasia has an increased risk of developing breast cancer within an early phase from diagnosis (e.g., within ten years of biopsy) or an increased risk of developing breast cancer at a late phase from diagnosis (e.g., at a point more than ten years of biopsy) are provided.
Lynn C Hartmann, Rochester MN
Specialties:
Internal Medicine, Medical Oncology, Gynecology
Work:
Mayo Medical School
200 1St St Sw, Rochester, MN 55905
200 1St St Sw, Rochester, MN 55905
Education:
Northwestern University (1983)
Quantitation Of Lobular Involution For Breast Cancer Risk Prediction
US Patent:
2010031, Dec 9, 2010
Filed:
Jan 21, 2009
Appl. No.:
12/863889
Inventors:
Lynn C. Hartmann - Rochester MN, US
Carol Reynolds - Rochester MN, US
Kevin P. McKian - Rochester MN, US
Carol Reynolds - Rochester MN, US
Kevin P. McKian - Rochester MN, US
International Classification:
C12Q 1/02
US Classification:
435 29
Abstract:
Methods for determining risk of developing breast cancer are described.
Novel Compositions And Methods For The Identification, Assessment, Prevention And Therapy Of Human Cancers
US Patent:
2003014, Jul 31, 2003
Filed:
Feb 8, 2002
Appl. No.:
10/071510
Inventors:
Edwin Clark - Ashland MA, US
Tallessyn Grenfell-Lee - Cambridge MA, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester MN, US
Jeffrey Brown - Arlington MA, US
Tallessyn Grenfell-Lee - Cambridge MA, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester MN, US
Jeffrey Brown - Arlington MA, US
Assignee:
Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C12Q001/68, G01N033/574
US Classification:
435/006000, 435/007230
Abstract:
The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of sensitivity and resistance markers. These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.
Compositions And Methods For The Identification, Assessment, Prevention And Therapy Of Human Cancers
US Patent:
7871775, Jan 18, 2011
Filed:
Dec 17, 2007
Appl. No.:
12/002783
Inventors:
Edwin Clark - Ashland MA, US
Tallessyn Grenfell-Lee - Cambridge MA, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester MN, US
Jeffrey L. Brown - Arlington MA, US
Gordon B. Mills - Houston TX, US
Tallessyn Grenfell-Lee - Cambridge MA, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester MN, US
Jeffrey L. Brown - Arlington MA, US
Gordon B. Mills - Houston TX, US
Assignee:
Millennium Pharmaceuticals, Inc - Cambridge MA
Mayo Foundation for Medical Edication and Research - Rochester MN
Board of Regents, The University of Texas System - Austin TX
Mayo Foundation for Medical Edication and Research - Rochester MN
Board of Regents, The University of Texas System - Austin TX
International Classification:
C12Q 1/68
US Classification:
435 6, 536 231
Abstract:
The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers. ” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers. ” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.
Compositions And Methods For The Identification, Assessment, Prevention And Therapy Of Ovarian Cancer
US Patent:
7470509, Dec 30, 2008
Filed:
Feb 7, 2003
Appl. No.:
10/361112
Inventors:
Andrew I. Damokosh - West Hartford CT, US
Natalia Iartchouk - Wayland MA, US
Edwin A. Clark - Pennington NJ, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester MN, US
Gordon B. Mills - Houston TX, US
Natalia Iartchouk - Wayland MA, US
Edwin A. Clark - Pennington NJ, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester MN, US
Gordon B. Mills - Houston TX, US
Assignee:
Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C12Q 1/68
US Classification:
435 6, 536 231, 536 235, 435 4
Abstract:
The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with sensitivity or resistance to a therapeutic agent. Thus, by examining the expression of the individual markers of a marker set, also referred to as the expression profile of the marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of the ovarian cancer.
Method For Cancer Prognosis Using Cellular Folate Vitamin Receptor Quantification
US Patent:
2009008, Mar 26, 2009
Filed:
Mar 30, 2006
Appl. No.:
11/887438
Inventors:
Philip Stewart Low - West Lafayette IN, US
Lynn C. Hartmann - Rochester MN, US
Christopher Paul Leamon - West Lafayette IN, US
Phil Ronald Ellis - West Lafayette IN, US
Lynn C. Hartmann - Rochester MN, US
Christopher Paul Leamon - West Lafayette IN, US
Phil Ronald Ellis - West Lafayette IN, US
Assignee:
Purdue Research Foundation - West Lafayette IN
International Classification:
G01N 33/574
US Classification:
435 723
Abstract:
The invention relates to a method for determining a prognosis for a cancer by quantifying vitamin receptor expression on the cancer cells. The method comprises the steps of quantifying vitamin receptor expression on the cancer cells, and determining a prognosis for the cancer. The invention also relates to methods and kits for determining the presence of vitamin receptors on cancer cells to select patients that should be treated with a therapy that utilizes vitamin receptor targeting and to develop a treatment regimen for such patients. The invention further relates to kits for performing the methods.
Immunity To Folate Receptors
US Patent:
8486412, Jul 16, 2013
Filed:
Jun 1, 2007
Appl. No.:
12/303054
Inventors:
Keith L. Knutson - Rochester MN, US
Lynn C. Hartmann - Rochester MN, US
Kimberly R. Kalli - Dover MN, US
Christopher J. Krco - Rochester MN, US
Lynn C. Hartmann - Rochester MN, US
Kimberly R. Kalli - Dover MN, US
Christopher J. Krco - Rochester MN, US
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:
A61K 38/10, C07K 4/12
US Classification:
4241851, 4241841, 4242771, 514 192, 514 193, 514 214, 514 215, 530326, 530806
Abstract:
This document provides methods and materials related to assessing immunity to folate receptors. For example, methods and materials for assessing FRα immunity in a mammal are provided. This document also provides methods and materials related to stimulating immunity to folate receptors.